Sökning: L773:1042 8194 OR L773:1029 2403 >
Cytarabine dose int...
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
-
- Abé, Christoph (författare)
- Karolinska Institutet,Karolinska Institute,Quantify Research AB
-
- Keto, Jaana (författare)
- Jazz Pharmaceuticals, Denmark
-
- Lilja, Mathias (författare)
- Quantify Research AB
-
visa fler...
-
- Konradsen, Mie (författare)
- Quantify Research AB
-
- Mesterton, Johan (författare)
- Karolinska Institute,Quantify Research AB
-
- Höglund, Martin (författare)
- Uppsala University
-
- Lazarevic, Vladimir (författare)
- Lund University,Lunds universitet,Leukemi, genetik, epidemiologi,Forskargrupper vid Lunds universitet,Leukemia, Genetics, Epidemiology,Lund University Research Groups,Skåne University Hospital
-
- Lehmann, Sören (författare)
- Uppsala University,Karolinska Institute,Uppsala University Hospital
-
- Juliusson, Gunnar (författare)
- Lund University,Lunds universitet,Leukemi, genetik, epidemiologi,Forskargrupper vid Lunds universitet,Leukemia, Genetics, Epidemiology,Lund University Research Groups,Skåne University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2024
- 2024
- Engelska.
-
Ingår i: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403.
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Since 1980’s, the established/standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). We compared the 7 + 3 regimen in older secondary/high-risk AML patientsfrom a clinical trial with a matched population from the Swedish AML Registrytreated withan increased cytarabine dose in induction and consolidation as recommended in the Swedish National Guidelines since 2005. After successfulpropensity score matching, 104 patients per group were included. The primary outcome was overall survival (OS), and standard dosed patients had a median OS of 6.4 versus 10.7 months with increased dose intensity (hazard ratio:0.69, p = 0.012), with 5-year OS of 8.7% and 18.1%, andremission rates of 36% and 60%, respectively (p < 0.001). Median OS after allogeneic hematopoietic cell transplantation (in 27.9% per group) was 10.4 and 20.7 months, respectively. We conclude that the more intensive cytarabine schedule seems to provide improved outcomes inthe investigated AML patient group.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Conventional 7 + 3 regimen
- external control arm
- hematopoietic cell transplantation
- overall survival
- real-world data
- standard of care
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas